Eosinophilic pneumonia prevention: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
No edit summary |
||
| Line 3: | Line 3: | ||
== Prevention of eosinophilic pneumonia == | == Prevention of eosinophilic pneumonia == | ||
* [[Relapse|Relapses]] occur in more than half the patients while decreasing or after stopping [[corticosteroids]]. | * [[Relapse|Relapses]] occur in more than half the patients while decreasing or after stopping [[corticosteroids]].<ref name="pmid23947590">{{cite journal| author=Liu D, Ahmet A, Ward L, Krishnamoorthy P, Mandelcorn ED, Leigh R et al.| title=A practical guide to the monitoring and management of the complications of systemic corticosteroid therapy. | journal=Allergy Asthma Clin Immunol | year= 2013 | volume= 9 | issue= 1 | pages= 30 | pmid=23947590 | doi=10.1186/1710-1492-9-30 | pmc=3765115 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=23947590 }}</ref> | ||
* Relapses typically can be treated with a dose of 20 mg per day of [[Prednisone|prednisone.]] | * Relapses typically can be treated with a dose of 20 mg per day of [[Prednisone|prednisone.]] | ||
* Clinical and functional follow-up is necessary. | * Clinical and functional follow-up is necessary.<ref name="pmid29206477">{{cite journal| author=De Giacomi F, Vassallo R, Yi ES, Ryu JH| title=Acute Eosinophilic Pneumonia: Causes, Diagnosis and Management. | journal=Am J Respir Crit Care Med | year= 2017 | volume= | issue= | pages= | pmid=29206477 | doi=10.1164/rccm.201710-1967CI | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=29206477 }}</ref> | ||
* Patients should be informed about the role of [[tobacco]] in the disease process and should be encouraged to quit.__NOTOC__ | * Patients should be informed about the role of [[tobacco]] in the disease process and should be encouraged to quit.__NOTOC__ | ||
{{Eosinophilic pneumonia}} | {{Eosinophilic pneumonia}} | ||
Latest revision as of 05:02, 2 March 2018
Overview
Relapses occur in more than half the patients while decreasing or after stopping corticosteroids. Relapses typically can be treated with a dose of 20 mg per day of prednisone.
Prevention of eosinophilic pneumonia
- Relapses occur in more than half the patients while decreasing or after stopping corticosteroids.[1]
- Relapses typically can be treated with a dose of 20 mg per day of prednisone.
- Clinical and functional follow-up is necessary.[2]
- Patients should be informed about the role of tobacco in the disease process and should be encouraged to quit.
|
Eosinophilic pneumonia Microchapters |
|
Diagnosis |
|
Treatment |
|
Case Studies |
|
Eosinophilic pneumonia prevention On the Web |
|
American Roentgen Ray Society Images of Eosinophilic pneumonia prevention |
|
Risk calculators and risk factors for Eosinophilic pneumonia prevention |
References
- ↑ Liu D, Ahmet A, Ward L, Krishnamoorthy P, Mandelcorn ED, Leigh R; et al. (2013). "A practical guide to the monitoring and management of the complications of systemic corticosteroid therapy". Allergy Asthma Clin Immunol. 9 (1): 30. doi:10.1186/1710-1492-9-30. PMC 3765115. PMID 23947590.
- ↑ De Giacomi F, Vassallo R, Yi ES, Ryu JH (2017). "Acute Eosinophilic Pneumonia: Causes, Diagnosis and Management". Am J Respir Crit Care Med. doi:10.1164/rccm.201710-1967CI. PMID 29206477.